Tearsheet

Teleflex (TFX)

Market Price (12/4/2025): $118.99 | Market Cap: $5.3 Bil
Sector: Health Care | Industry: Health Care Equipment

Teleflex (TFX)

Market Price (12/4/2025): $118.99
Market Cap: $5.3 Bil
Sector: Health Care
Industry: Health Care Equipment

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 12%	Weak multi-year price returns 2Y Excs Rtn is -96%, 3Y Excs Rtn is -118%	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.6%
1	Low stock price volatility Vol 12M is 40%
2	Megatrend and thematic drivers Megatrends include Aging Population & Chronic Disease, and Medical Device Innovation. Themes include Geriatric Care, Minimally Invasive Surgical Solutions, Show more.

0	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 12%
1	Low stock price volatility Vol 12M is 40%
2	Megatrend and thematic drivers Megatrends include Aging Population & Chronic Disease, and Medical Device Innovation. Themes include Geriatric Care, Minimally Invasive Surgical Solutions, Show more.
3	Weak multi-year price returns 2Y Excs Rtn is -96%, 3Y Excs Rtn is -118%
4	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.6%

Valuation, Metrics & Events

	12/4/25	2024	2023	2022	2021
Share Price CYE	$118.99	$176.02	$245.02	$243.84	$319.22
Market Cap CYE ($ Bil)	5.3	8.2	11.5	11.4	15.0
Total Debt ($ Bil)	2.8	1.8	1.9	1.8	2.0
Total Cash ($ Bil)	0.4	0.3	0.2	0.3	0.4
Enterprise Value ($ Bil)	7.7	10.0	13.4	13.2	17.0
Valuation Ratios
P/S TTM	1.7	2.7	3.9	4.2	5.5
P/EBIT TTM	-23.5	52.4	22.6	23.4	24.9
P/E TTM	-16.5	119.6	32.9	32.2	31.6
Sector Ratios
P/S TTM (Sector)	3.7	3.5	3.9	4.4	7.1
P/EBIT TTM (Sector)	-1.4	-1.3	-1.3	-1.2	-2.6
P/E TTM (Sector)	-1.6	-1.5	-1.5	-1.3	-2.8

	12/4/25	2024	2023
Share Price CYE	$118.99	$176.02	$245.02
Market Cap CYE ($ Bil)	5.3	8.2	11.5
Total Debt ($ Bil)	2.8	1.8	1.9
Total Cash ($ Bil)	0.4	0.3	0.2
Enterprise Value ($ Bil)	7.7	10.0	13.4
Valuation Ratios
P/S TTM	1.7	2.7	3.9
P/EBIT TTM	-23.5	52.4	22.6
P/E TTM	-16.5	119.6	32.9
Sector Ratios
P/S TTM (Sector)	3.7	3.5	3.9
P/EBIT TTM (Sector)	-1.4	-1.3	-1.3
P/E TTM (Sector)	-1.6	-1.5	-1.5

	TFX	S&P 500
REVENUE GROWTH	FAIR
Rev LTM ($ Bil)	3.2
Rev Chg Q	19.4%	7.1%
Rev Chg LTM	5.4%	6.1%
Rev Chg 3Y Avg	4.5%	5.5%
PROFITABILITY	POOR
Op Inc LTM ($ Bil)	0.6
CFO LTM ($ Bil)	0.4
Net Inc LTM ($ Bil)	-0.3
Op Mgn LTM	17.6%	18.8%
CFO/Rev LTM	12.3%	20.5%
Net Inc Mgn	-10.3%	13.1%
VALUATION	MODERATE
P/S	1.7	3.2
P/CFO	13.8	15.8
P/FCF	20.5	20.5
P/E	-16.5	23.5
STABILITY	POOR
Debt/Equity	0.51	0.20
Cash/Assets	0.04	0.07

AI Generated Analysis | Feedback

Metric	Value	Date	Source
Active Patents	1743	5212024	Link
Pipeline Products in Development	21	5212024	Link
Revenue from Vascular Intervention Business Acquisition (Second Half 2025 Projection)	€177 million ($204 million)	7032025	Link
Number of Manufacturing Facilities (Planned for RemainCo post-separation)	7	2272025	Link
Number of Customers	80,000+	12312022	Link
Net Promoter Score (Americas)	54	12312022	Link
Market Position in Anesthesia Disposables	Leading	1122021	Link
Market Position in Vascular Access Devices	Leading Player	2212025	Link

Recent
11/06/2025	Earnings Release	Rev: $913 Mil (A) vs. $936 Mil (E) EPS: 3.67 (A) vs. $3.38 (E)
11/14/2025	Dividend	Amount: $0.34 Payment On: 12/15/2025
Upcoming
2/26/2026	Earnings Release	Rev: - EPS: -

TFX Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Generated Analysis | Feedback

Here are the key points explaining the movement of Teleflex (TFX) stock from approximately August 31, 2025, to December 4, 2025:

1. Teleflex reported its Third Quarter 2025 financial results on November 6, 2025, which included a narrowing of its full-year 2025 adjusted EPS guidance to $14.00-$14.20 from the previous range of $13.90-$14.30.

2. Concurrently with the Q3 earnings report, Teleflex also reduced its adjusted revenue growth guidance for 2025 to a range of 8% to 8.5%, down from the prior expectation of 8.5% to 9.5%.

Stock Movement Drivers

Fundamental Drivers

The -5.2% change in TFX stock from 9/3/2025 to 12/3/2025 was primarily driven by a -9.7% change in the company's P/S Multiple.

	9032025	12032025	Change
Stock Price ($)	125.66	119.12	-5.20%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	3041.34	3189.99	4.89%
P/S Multiple	1.83	1.65	-9.69%
Shares Outstanding (Mil)	44.27	44.24	0.07%
Cumulative Contribution			-5.20%

LTM = Last Twelve Months as of date shown

Market Drivers

9/3/2025 to 12/3/2025

	Return	Correlation
TFX	-5.2%
Market (SPY)	6.2%	39.3%
Sector (XLV)	13.3%	50.3%

Fundamental Drivers

The -2.4% change in TFX stock from 6/4/2025 to 12/3/2025 was primarily driven by a -11.0% change in the company's P/S Multiple.

	6042025	12032025	Change
Stock Price ($)	122.03	119.12	-2.38%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	3010.14	3189.99	5.97%
P/S Multiple	1.86	1.65	-10.99%
Shares Outstanding (Mil)	45.78	44.24	3.37%
Cumulative Contribution			-2.49%

LTM = Last Twelve Months as of date shown

Market Drivers

6/4/2025 to 12/3/2025

	Return	Correlation
TFX	-2.4%
Market (SPY)	15.1%	37.2%
Sector (XLV)	16.9%	43.8%

Fundamental Drivers

The -36.0% change in TFX stock from 12/3/2024 to 12/3/2025 was primarily driven by a -42.5% change in the company's P/S Multiple.

	12032024	12032025	Change
Stock Price ($)	186.06	119.12	-35.98%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	3025.82	3189.99	5.43%
P/S Multiple	2.87	1.65	-42.50%
Shares Outstanding (Mil)	46.72	44.24	5.32%
Cumulative Contribution			-36.16%

LTM = Last Twelve Months as of date shown

Market Drivers

12/3/2024 to 12/3/2025

	Return	Correlation
TFX	-36.0%
Market (SPY)	14.3%	37.8%
Sector (XLV)	7.0%	45.7%

Fundamental Drivers

The -49.7% change in TFX stock from 12/4/2022 to 12/3/2025 was primarily driven by a -58.5% change in the company's P/S Multiple.

	12042022	12032025	Change
Stock Price ($)	236.96	119.12	-49.73%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	2794.96	3189.99	14.13%
P/S Multiple	3.98	1.65	-58.46%
Shares Outstanding (Mil)	46.91	44.24	5.69%
Cumulative Contribution			-49.89%

LTM = Last Twelve Months as of date shown

Market Drivers

12/4/2023 to 12/3/2025

	Return	Correlation
TFX	-47.1%
Market (SPY)	53.2%	34.8%
Sector (XLV)	20.8%	45.4%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
TFX Return	10%	-20%	-24%	0%	-28%	-34%	-68%
Peers Return	1%	15%	-10%	19%	3%	-10%	16%
S&P 500 Return	16%	27%	-19%	24%	23%	16%	112%
Monthly Win Rates [3]
TFX Win Rate	58%	33%	50%	50%	50%	50%
Peers Win Rate	33%	38%	35%	48%	42%	38%
S&P 500 Win Rate	58%	75%	42%	67%	75%	70%
Max Drawdowns [4]
TFX Max Drawdown	-40%	-29%	-43%	-28%	-30%	-41%
Peers Max Drawdown	-34%	-4%	-23%	-1%	-12%	-14%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: BSX, ROP, CNMD, DAVI, EMI. See TFX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/3/2025 (YTD)

How Low Can It Go

Unique Key	Event	TFX	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-59.6%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	147.4%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-43.0%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	75.4%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	128 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-20.7%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	26.1%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	199 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-55.7%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	125.9%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	1463 days	1480 days

Compare to BSX, ROP, CNMD, DAVI, EMI

In The Past

Teleflex's stock fell -59.6% during the 2022 Inflation Shock from a high on 4/28/2021. A -59.6% loss requires a 147.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Teleflex (TFX)

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

AI Generated Analysis | Feedback

Medtronic for essential hospital medical devices.

A specialized Johnson & Johnson for hospital medical supplies.

Stryker for a broader range of critical care and surgical devices.

AI Generated Analysis | Feedback

```html

Vascular Access Products: A comprehensive portfolio of catheters, guide wires, and related devices used for delivering fluids and monitoring patients.
Anesthesia Products: Airway management devices, including laryngeal mask airways (LMAs) and endotracheal tubes, along with regional anesthesia solutions.
Surgical Products: Surgical instruments, ligation systems, and fascial closure devices for various open and minimally invasive surgical procedures.
Urology Products: Catheters and related devices for bladder management and other urological care applications.
Interventional Products: Specialized guide wires, catheters, and access devices primarily used in interventional cardiology and radiology procedures.
Original Equipment Manufacturer (OEM) Components: Custom extrusion and precision components provided to other medical device manufacturers.

```

AI Generated Analysis | Feedback

Teleflex (TFX) - Major Customers

Teleflex (TFX) sells primarily to other companies and healthcare organizations, rather than directly to individuals. As a global provider of medical devices, its customer base is highly fragmented across thousands of healthcare facilities and purchasing organizations worldwide. Therefore, it does not typically disclose a few specific "major customers" by name and stock symbol in the way a component supplier might name a finished goods manufacturer.

However, the categories of major customers for Teleflex include:

Hospitals and Acute Care Facilities: These are the primary end-users of Teleflex's surgical, critical care, vascular access, and anesthesia products. This includes general hospitals, specialized hospitals, and university medical centers globally.
Ambulatory Surgery Centers (ASCs) and Clinics: As healthcare delivery shifts towards outpatient settings, ASCs and various specialized clinics represent a growing customer segment for many of Teleflex's less invasive products and supplies.
Integrated Delivery Networks (IDNs): In the United States, IDNs are large healthcare systems that own and operate multiple hospitals, clinics, and other healthcare facilities. They often make purchasing decisions centrally, making them significant customers.
Group Purchasing Organizations (GPOs): While not direct end-users, GPOs are crucial intermediaries, particularly in the U.S. They negotiate contracts for medical products and services on behalf of their member hospitals, IDNs, and other healthcare providers. Teleflex works closely with major GPOs to gain access to their extensive member networks.
Governmental Healthcare Providers: This includes national health services (e.g., NHS in the UK), Veterans Affairs (VA) hospitals in the U.S., and other public healthcare systems around the world.

Due to the nature of the medical device industry, these customers are typically private organizations, government entities, or large healthcare systems that are not publicly traded as individual entities for the purpose of identifying "customer symbols."

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

Liam J. Kelly, Chairman, President and Chief Executive Officer

Mr. Kelly became Chairman of the Teleflex Board on May 1, 2020, and has served as the company's President and Chief Executive Officer since January 1, 2018. He joined Teleflex in April 2009 and held various executive leadership roles, including President of EMEA, Executive Vice President and President, International, Executive Vice President and President, Americas, and Executive Vice President and Chief Operating Officer. Prior to joining Teleflex, Mr. Kelly held senior leadership positions at Hill-Rom Holdings, Inc., a medical device company, from 2002 to 2009, where he served as Vice President of International Marketing and Product Development and as Managing Director of their UK & Ireland businesses.

John R. Deren, Executive Vice President and Chief Financial Officer

Mr. Deren has been the Executive Vice President and Chief Financial Officer of Teleflex since April 2, 2025. He previously served as the Chief Accounting Officer and Vice President of the company. Before Teleflex, Mr. Deren was the Vice President and Global Controller at Trinseo. Earlier in his career, he served as the Assistant Controller of Exelon Generation and of Rohm and Haas Co.

Jay K. White, Corporate Vice President and President, Global Commercial

Mr. White serves as Corporate Vice President and President, Global Commercial at Teleflex.

Daniel V. Logue, Corporate Vice President, General Counsel and Secretary

Mr. Logue holds the position of Corporate Vice President, General Counsel and Secretary at Teleflex.

James P. Winters, Corporate Vice President, Manufacturing and Supply Chain

Mr. Winters is the Corporate Vice President, Manufacturing and Supply Chain for Teleflex.

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

Teleflex (symbol: TFX) operates in various medical technology segments, with addressable markets as follows:

Vascular Access: The global vascular access device market was valued at approximately USD 5.78 billion in 2023 and is projected to reach USD 9.40 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.2%. Another estimate values the market at USD 5.99 billion in 2024, expected to reach USD 9.05 billion by 2030, with a CAGR of 7.1%. North America is anticipated to hold a major share of this market.
Anesthesia and Respiratory Devices: The global market for anesthesia and respiratory devices was estimated at USD 56.3 billion in 2024 and is expected to grow to USD 91.5 billion by 2033, with a CAGR of 5.6% from 2025 to 2033. More specifically for anesthesia devices, the global market size was estimated at USD 17.45 billion in 2024 and is projected to reach USD 42.80 billion by 2035, growing at a CAGR of 8.50% from 2025 to 2035. The U.S. anesthesia devices market was estimated at USD 6.49 billion in 2024 and is projected to reach approximately USD 13.25 billion by 2034. North America held the largest revenue share in the anesthesia and respiratory devices market in 2024.
Interventional Cardiology and Peripheral Vascular: Teleflex is committed to investing in the estimated USD 10 billion global interventional cardiology and peripheral vascular market. The global interventional cardiology devices market size was estimated at USD 10.57 billion in 2024 and is projected to reach USD 19.75 billion by 2033, growing at a CAGR of 7.25% from 2025 to 2033. Another report indicates the global interventional cardiology devices market size was USD 16.69 billion in 2024, projected to grow to USD 29.32 billion by 2032 with a CAGR of 7.3% from 2025. North America dominated the interventional cardiology devices market in 2024 with a 45.06% revenue share.
Interventional Urology (within Urology Devices): The global urology devices market was estimated at USD 36.8 billion in 2024 and is expected to grow from USD 39.3 billion in 2025 to USD 73.5 billion in 2034, at a CAGR of 7.2%. Another source indicates the global urology devices market size was USD 36.34 billion in 2024, with a projection to reach USD 64.33 billion by 2032, exhibiting a CAGR of 7.4%. North America held the largest market share in the global urology devices market in 2024 at 42.5%. The U.S. urology surgical instruments market alone is expected to reach US$6,497.7 million by 2030, growing at a CAGR of 7.5% from 2025 to 2030. Teleflex's Interventional Urology segment includes products like the UroLift System and Barrigel.
Surgical: The global surgical retractors market size, a specific area within surgical products, is expected to reach USD 1.81 billion by 2025.
Cardiac Assist Devices: The global cardiac assist devices market was valued at USD 2.89 billion in 2023 and is projected to reach USD 6.23 billion by 2030, growing at a CAGR of 13.70% from 2024 to 2030. Another forecast estimates an 8.0% CAGR for the market from 2023 to 2031. North America is predicted to experience the fastest growth in this market.

For the product areas of Emergency Medicine and OEM (Original Equipment Manufacturing), specific addressable market sizes for Teleflex's offerings were not readily available in the search results. Therefore, the market size for these categories is null.

AI Generated Analysis | Feedback

Teleflex (TFX) is expected to drive future revenue growth over the next two to three years through several key strategies and product line expansions:

Strategic Acquisitions and Integration: The acquisition and integration of the Vascular Intervention business, particularly the former BIOTRONIK assets, is a significant driver. This acquisition is expected to contribute substantially to revenue, with management anticipating the combined Interventional business to generate over $800 million in annual revenues. The acquired portfolio alone was projected to bring in $204 million in the second half of 2025.
Growth in the Interventional Segment: Beyond the recent acquisitions, Teleflex anticipates continued strong performance from its broader Interventional segment. Key products like intra-aortic balloon pumps (IABP), OnControl, and complex catheters have been identified as strong contributors to this segment's growth, even as the company monitors order rates for IABPs.
Expansion of the Global Vascular Access Portfolio: The company's Vascular Access segment, which includes products such as peripheral access, EZ-IO, and central access products, is consistently cited as a strong performer and a driver of revenue increases.
Increased Adoption and Geographic Expansion of Barrigel: Following the acquisition of Palette Life Sciences, Barrigel revenue has been a notable growth driver within Interventional Urology. Teleflex's strategy includes expanding the usage and geographic availability of Barrigel products to further contribute to revenue growth.

AI Generated Analysis | Feedback

Capital Allocation Decisions (Last 3-5 Years)

Share Repurchases

    In August 2024, Teleflex's Board of Directors authorized a share repurchase program of up to $500 million, which included a $200 million accelerated share repurchase (ASR).
    As part of this authorization, the company initiated a $300 million ASR in March 2025, which was completed on April 9, 2025.


Share Issuance

    Teleflex's shares outstanding have shown a declining trend, with 0.044 billion shares outstanding as of June 30, 2025, a 6.4% decline year-over-year.
    As of November 4, 2025, there were 44,194,408 shares of common stock outstanding.


Inbound Investments

    Following the announcement of its intent to separate into two independent companies ("NewCo" and "RemainCo"), Teleflex received significant third-party interest and a number of inbound expressions of interest in acquiring NewCo.


Outbound Investments

    In February 2025, Teleflex entered into an agreement to acquire substantially all of BIOTRONIK SE & Co. KG's Vascular Intervention business for an estimated cash payment of approximately €760 million (approximately $825.2 million).
    This acquisition was completed in July 2025, expanding Teleflex's presence in the interventional cardiology and peripheral vascular markets.
    The BIOTRONIK Vascular Intervention acquisition was funded by a $700 million delayed draw term loan and additional revolver borrowings, increasing total borrowings to $2,681,250.


Capital Expenditures

    Over the last 12 months (as of November 2025), Teleflex reported capital expenditures of -$126.61 million.
    Recent quarterly capital expenditure levels have generally remained in the $20 million to $40 million range.
    The company expects to incur an additional $5 million to $7 million in capital expenditures primarily in 2026 and 2027 related to the VI Business Integration plan.

Better Bets than Teleflex (TFX)

	TFX	Better Performance than TFX
Metric	Value	INDUSTRY: Health Care Equipment
Rev Chg LTM	5.4%	ISRG (22.2%), BSX (21.6%), SYK (11.0%), IDXX (8.4%), ABT (6.4%)
Rev Chg 3Y Avg	4.5%	ISRG (16.3%), BSX (15.6%), RMD (13.3%), SYK (10.8%), IDXX (7.7%)
Op Mgn LTM	17.6%	IDXX (31.3%), ISRG (29.3%), SYK (19.6%), MDT (19.4%), BSX (19.2%)
CFO/Rev LTM	12.3%	ISRG (30.8%), BSX (23.9%), MDT (20.9%), ABT (20.8%), SYK (19.8%)
FCF/Rev LTM	8.3%	ISRG (23.6%), BSX (18.7%), SYK (16.7%), ABT (15.8%), MDT (15.5%)
Total Yield	-5.5%	ABT (7.7%), MDT (7.4%), SYK (3.0%), BSX (1.9%), ISRG (1.7%)
P/S	1.7	ENOV (0.8), BAX (1.1), BLCO (1.1), BRKR (1.4), GEHC (1.7)
P/Op Inc	9.6	EMBC (2.0), AHCO (5.7)

	TFX	Better Performance than TFX
Metric	Value	SECTOR: Health Care
Rev Chg LTM	5.4%	LLY (36.8%), ISRG (22.2%), UNH (10.5%), ABBV (7.4%), ABT (6.4%)
Rev Chg 3Y Avg	4.5%	LLY (23.4%), ISRG (16.3%), UNH (11.4%), AMGN (11.2%), JNJ (6.1%)
Op Mgn LTM	17.6%	LLY (43.0%), MRK (34.9%), JNJ (26.2%), ABBV (24.1%), TMO (18.4%)
CFO/Rev LTM	12.3%	ABBV (35.0%), MRK (26.6%), JNJ (26.3%), LLY (20.5%), TMO (17.5%)
FCF/Rev LTM	8.3%	ABBV (33.0%), MRK (20.3%), JNJ (20.3%), ABT (15.8%), TMO (14.0%)
Total Yield	-5.5%	MRK (13.0%), JNJ (8.4%), UNH (8.1%), ABBV (3.4%), LLY (2.7%)
P/S	1.7	CVS (0.2), MCK (0.2), ELV (0.4), UNH (0.7), HCA (1.4)
P/Op Inc	9.6	BMY (8.0), CVS (8.9), HCA (9.2), MRK (9.4), PFE (9.4)

	TFX	Better Performance than TFX
Metric	Value	ALL OTHER SECTORS
Rev Chg LTM	5.4%	NVDA (71.6%), MSFT (15.6%), GOOGL (13.4%), AMZN (10.9%), AAPL (6.0%)
Rev Chg 3Y Avg	4.5%	NVDA (92.0%), AVGO (24.0%), MSFT (13.2%), AMZN (11.3%), GOOGL (11.0%)
Op Mgn LTM	17.6%	NVDA (58.1%), MSFT (46.3%), AVGO (39.0%), GOOGL (32.2%), AAPL (31.9%)
CFO/Rev LTM	12.3%	MSFT (50.0%), NVDA (46.6%), GOOGL (39.3%), AAPL (26.6%), AMZN (18.1%)
FCF/Rev LTM	8.3%	NVDA (43.6%), AVGO (41.6%), MSFT (26.6%), AAPL (23.5%), GOOGL (19.1%)
Total Yield	-5.5%	GOOGL (4.6%), MSFT (3.4%), AMZN (3.0%), AAPL (3.0%), NVDA (2.3%)
P/S	1.7	WMT (1.1), XOM (1.4), COST (1.5), CVX (1.6), T (1.6)
P/Op Inc	9.6	VZ (5.9), BUD (7.7), BN (8.1), T (8.3), COP (9.4)

		Best Bets In Health Care Sector
	TFX
What You Pay
P/E	-16.5
P/EBIT	-23.5
What You Get
Rev Chg Q	19.4%
Rev Chg LTM	5.4%
Rev Chg 3Y Avg	4.5%
FCF/Rev 3Y Avg	12.0%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic	Date
0	DASHBOARDS
1	How Low Can Teleflex Stock Really Go?	Return
2	Teleflex vs Merck: Which Is A Better Investment?	Counter-Intuitive Comparisons
3	How Does Teleflex Stock Stack Up Against Its Peers?	Peer Comparison
4	Better Bet Than TFX Stock: Pay Less Than Teleflex To Get More From UNH, HCA
5	Better Bet Than TFX Stock: Pay Less Than Teleflex To Get More From UNH, HCA
6	TFX Dip Buy Analysis
7	Teleflex Total Shareholder Return (TSR): -27.0% in 2024 and -17.1% 3-yr compounded annual returns (below peer average)
8	Teleflex (TFX) worth $6.5 Bil (down $-1.8 Bil), still more valuable than APA	Notification
9	Teleflex (TFX) Operating Cash Flow Comparison	Financials
10	Teleflex (TFX) Net Income Comparison	Financials
11	ARTICLES
12	Should You Pick Teleflex Stock After 20% Gains This Month?		December 1st, 2023
13	Should You Buy Teleflex Stock At $225?		November 25th, 2022
14	What’s Next For Teleflex Stock After Its Recent PTD Recall?		November 30th, 2021
15	Will Teleflex Stock Rise After A 7% Fall Last Week?		July 19th, 2021
16	Teleflex Stock Looks Fully Valued At $370		November 24th, 2020

	Title
0	DASHBOARDS
1	How Low Can Teleflex Stock Really Go?
2	Teleflex vs Merck: Which Is A Better Investment?
3	How Does Teleflex Stock Stack Up Against Its Peers?
4	Better Bet Than TFX Stock: Pay Less Than Teleflex To Get More From UNH, HCA
5	Better Bet Than TFX Stock: Pay Less Than Teleflex To Get More From UNH, HCA
6	TFX Dip Buy Analysis
7	Teleflex Total Shareholder Return (TSR): -27.0% in 2024 and -17.1% 3-yr compounded annual returns (below peer average)
8	Teleflex (TFX) worth $6.5 Bil (down $-1.8 Bil), still more valuable than APA
9	Teleflex (TFX) Operating Cash Flow Comparison
10	Teleflex (TFX) Net Income Comparison
11	ARTICLES
12	Should You Pick Teleflex Stock After 20% Gains This Month?
13	Should You Buy Teleflex Stock At $225?
14	What’s Next For Teleflex Stock After Its Recent PTD Recall?
15	Will Teleflex Stock Rise After A 7% Fall Last Week?
16	Teleflex Stock Looks Fully Valued At $370

Trade Ideas

Select past ideas related to TFX. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	10.0%	10.0%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.7%	-7.7%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	6.9%	6.9%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	11.5%	11.5%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	8.9%	8.9%	-5.1%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	10.0%	10.0%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.7%	-7.7%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	6.9%	6.9%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	11.5%	11.5%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	8.9%	8.9%	-5.1%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
MPLT	MapLight Therapeutics	0.7	31.3%
AEVA	Aeva Technologies	0.8	25.7%	188.2%
DC	Dakota Gold	0.6	19.7%	150.9%
SERV	Serve Robotics	0.7	18.2%	-12.6%
ACDC	ProFrac	0.7	17.6%	-45.0%
HY	Hyster Yale	0.6	15.6%	-29.9%
AEO	American Eagle Outfitters	4.1	15.1%	49.7%
BEAM	Beam Therapeutics	2.7	14.4%	7.8%
GOSS	Gossamer Bio	0.8	14.4%	278.1%
FTRE	Fortrea	1.3	14.4%	-21.8%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
PSTG	Pure Storage	22.6	-27.3%	12.1%
GTLB	GitLab	6.3	-12.8%	-32.9%
CTEV	Claritev	0.7	-11.3%
FBYD	Falcons Beyond Global	0.7	-11.2%	131.2%
ACHC	Acadia Healthcare	1.3	-10.9%	-63.0%
ULS	UL Solutions	16.0	-10.7%	60.4%
HPK	HighPeak Energy	0.7	-10.6%	-59.8%
OS	OneStream	3.5	-10.4%	-35.0%
ARE	Alexandria Real Estate Equities	8.2	-10.1%	-47.9%
THO	Thor Industries	5.3	-9.5%	6.6%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
HPP	Hudson Pacific Properties	6.3	641.5%	-34.3%
TLRY	Tilray Brands	7.5	618.1%	-46.9%
TMC	TMC The Metals	2.8	42.2%	589.3%
VERA	Vera Therapeutics	2.6	40.2%	-2.4%
ARWR	Arrowhead Pharmaceuticals	9.0	39.1%	246.1%
TE	T1 Energy	0.7	37.4%
MPLT	MapLight Therapeutics	0.7	32.1%
AEVA	Aeva Technologies	0.8	31.1%	188.2%
AMKR	Amkor Technology	10.9	30.2%	73.4%
DC	Dakota Gold	0.6	30.2%	150.9%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
JANX	Janux Therapeutics	1.1	-50.7%	-68.0%
VTYX	Ventyx Biosciences	0.6	-25.0%	258.0%
CTEV	Claritev	0.7	-23.5%
AMBA	Ambarella	3.0	-22.9%	-3.6%
FULC	Fulcrum Therapeutics	0.6	-21.5%	92.8%
PD	PagerDuty	1.1	-20.5%	-33.9%
NTNX	Nutanix	12.7	-19.3%	-22.4%
CNK	Cinemark	2.6	-18.0%	-25.2%
PSTG	Pure Storage	22.6	-17.2%	12.1%
ZS	Zscaler	38.1	-15.9%	35.1%

1 Month Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
OLMA	Olema Pharmaceuticals	2.3	223.6%	367.4%
COGT	Cogent Biosciences	5.4	152.6%	402.1%
CDTX	Cidara Therapeutics	5.9	115.1%	722.1%
IRWD	Ironwood Pharmaceuticals	0.6	100.5%	-15.8%
TERN	Terns Pharmaceuticals	2.5	95.9%	396.2%
FRGE	Forge Global	0.6	90.3%	217.8%
SGML	Sigma Lithium	1.1	87.3%	-10.6%
INSP	Inspire Medical Systems	4.0	82.8%	-27.3%
NPCE	NeuroPace	0.6	77.2%	48.9%
ALMS	Alumis	0.6	71.9%	-0.3%

1 Month Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
UP	Wheels Up Experience	0.4	-52.7%	-62.4%
CCOI	Cogent Communications	0.9	-51.9%	-72.9%
SMR	NuScale Power	3.0	-50.7%	12.3%
FRMI	Fermi	10.3	-47.5%
AMSC	American Superconductor	1.4	-47.2%	30.1%
TLRY	Tilray Brands	7.5	-46.1%	-46.9%
BTDR	Bitdeer Technologies	2.4	-44.8%	-41.8%
EXOD	Exodus Movement	0.4	-43.1%	-53.3%
STUB	Stubhub	3.5	-39.8%
METC	Ramaco Resources	1.0	-39.4%	66.9%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
MPLT	MapLight Therapeutics	0.7	31.3%
AEVA	Aeva Technologies	0.8	25.7%	188.2%
DC	Dakota Gold	0.6	19.7%	150.9%
SERV	Serve Robotics	0.7	18.2%	-12.6%
ACDC	ProFrac	0.7	17.6%	-45.0%
HY	Hyster Yale	0.6	15.6%	-29.9%
AEO	American Eagle Outfitters	4.1	15.1%	49.7%
BEAM	Beam Therapeutics	2.7	14.4%	7.8%
GOSS	Gossamer Bio	0.8	14.4%	278.1%
FTRE	Fortrea	1.3	14.4%	-21.8%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
PSTG	Pure Storage	22.6	-27.3%	12.1%
GTLB	GitLab	6.3	-12.8%	-32.9%
CTEV	Claritev	0.7	-11.3%
FBYD	Falcons Beyond Global	0.7	-11.2%	131.2%
ACHC	Acadia Healthcare	1.3	-10.9%	-63.0%
ULS	UL Solutions	16.0	-10.7%	60.4%
HPK	HighPeak Energy	0.7	-10.6%	-59.8%
OS	OneStream	3.5	-10.4%	-35.0%
ARE	Alexandria Real Estate Equities	8.2	-10.1%	-47.9%
THO	Thor Industries	5.3	-9.5%	6.6%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
HPP	Hudson Pacific Properties	6.3	641.5%	-34.3%
TLRY	Tilray Brands	7.5	618.1%	-46.9%
TMC	TMC The Metals	2.8	42.2%	589.3%
VERA	Vera Therapeutics	2.6	40.2%	-2.4%
ARWR	Arrowhead Pharmaceuticals	9.0	39.1%	246.1%
TE	T1 Energy	0.7	37.4%
MPLT	MapLight Therapeutics	0.7	32.1%
AEVA	Aeva Technologies	0.8	31.1%	188.2%
AMKR	Amkor Technology	10.9	30.2%	73.4%
DC	Dakota Gold	0.6	30.2%	150.9%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
JANX	Janux Therapeutics	1.1	-50.7%	-68.0%
VTYX	Ventyx Biosciences	0.6	-25.0%	258.0%
CTEV	Claritev	0.7	-23.5%
AMBA	Ambarella	3.0	-22.9%	-3.6%
FULC	Fulcrum Therapeutics	0.6	-21.5%	92.8%
PD	PagerDuty	1.1	-20.5%	-33.9%
NTNX	Nutanix	12.7	-19.3%	-22.4%
CNK	Cinemark	2.6	-18.0%	-25.2%
PSTG	Pure Storage	22.6	-17.2%	12.1%
ZS	Zscaler	38.1	-15.9%	35.1%

Peer Comparisons for Teleflex

Peers to compare with:

Financials

	TFX	BSX	ROP	CNMD	DAVI	EMI	Median
Name	Teleflex	Boston S.	Roper Te.	Conmed	Davion H.	Encore M.
Mkt Price	119.12	98.57	445.89	44.35	-	-	108.84
Mkt Cap	5.3	146.1	48.0	1.4	-	-	26.6
Rev LTM	3,190	19,350	7,721	1,347	-	-	5,455
Op Inc LTM	561	3,720	2,172	118	-	-	1,367
FCF LTM	264	3,628	2,406	149	-	-	1,335
FCF 3Y Avg	365	2,378	1,995	118	-	-	1,180
CFO LTM	391	4,626	2,524	168	-	-	1,458
CFO 3Y Avg	478	3,305	2,101	135	-	-	1,289

Growth & Margins

	TFX	BSX	ROP	CNMD	DAVI	EMI	Median
Name	Teleflex	Boston S.	Roper Te.	Conmed	Davion H.	Encore M.
Rev Chg LTM	5.4%	21.6%	14.0%	4.6%	-	-	9.7%
Rev Chg 3Y Avg	4.5%	15.6%	14.1%	8.1%	-	-	11.1%
Rev Chg Q	19.4%	20.3%	14.3%	6.7%	-	-	16.9%
QoQ Delta Rev Chg LTM	4.9%	4.6%	3.4%	1.6%	-	-	4.0%
Op Mgn LTM	17.6%	19.2%	28.1%	8.8%	-	-	18.4%
Op Mgn 3Y Avg	18.3%	18.0%	28.3%	10.0%	-	-	18.1%
QoQ Delta Op Mgn LTM	-1.9%	0.9%	0.1%	-4.2%	-	-	-0.9%
CFO/Rev LTM	12.3%	23.9%	32.7%	12.4%	-	-	18.2%
CFO/Rev 3Y Avg	15.7%	19.8%	30.4%	10.4%	-	-	17.8%
FCF/Rev LTM	8.3%	18.7%	31.2%	11.1%	-	-	14.9%
FCF/Rev 3Y Avg	12.0%	14.1%	28.9%	9.1%	-	-	13.1%

Valuation

	TFX	BSX	ROP	CNMD	DAVI	EMI	Median
Name	Teleflex	Boston S.	Roper Te.	Conmed	Davion H.	Encore M.
Mkt Cap	5.3	146.1	48.0	1.4	-	-	26.6
P/S	1.7	7.5	6.9	1.1	-	-	4.3
P/EBIT	-23.5	40.1	23.4	12.3	-	-	17.9
P/E	-16.5	51.8	34.2	22.7	-	-	28.4
P/CFO	13.8	31.3	21.3	8.7	-	-	17.6
Total Yield	-5.5%	1.9%	3.6%	6.1%	-	-	2.8%
Dividend Yield	0.6%	0.0%	0.6%	1.7%	-	-	0.6%
FCF Yield 3Y Avg	4.3%	2.0%	3.6%	6.3%	-	-	4.0%
D/E	0.5	0.1	0.2	0.6	-	-	0.3
Net D/E	0.4	0.1	0.2	0.6	-	-	0.3

Returns

	TFX	BSX	ROP	CNMD	DAVI	EMI	Median
Name	Teleflex	Boston S.	Roper Te.	Conmed	Davion H.	Encore M.
1M Rtn	-2.7%	-0.0%	-0.6%	-1.1%	-	-	-0.9%
3M Rtn	-5.2%	-8.3%	-14.8%	-15.8%	-	-	-11.6%
6M Rtn	-2.4%	-3.8%	-21.3%	-21.0%	-	-	-12.4%
12M Rtn	-36.0%	9.0%	-20.9%	-40.0%	-	-	-28.4%
3Y Rtn	-49.7%	111.5%	2.2%	-49.3%	-	-	-23.5%
1M Excs Rtn	-2.7%	0.0%	-0.6%	-1.1%	-	-	-0.8%
3M Excs Rtn	-12.8%	-13.5%	-20.6%	-23.9%	-	-	-17.0%
6M Excs Rtn	-17.1%	-18.5%	-36.0%	-35.7%	-	-	-27.1%
12M Excs Rtn	-51.1%	-4.8%	-34.3%	-52.8%	-	-	-42.7%
3Y Excs Rtn	-118.5%	52.3%	-65.8%	-116.3%	-	-	-91.0%

Comparison Analyses

	Title
0	How Does Teleflex Stock Stack Up Against Its Peers?
1	Why TFX With 24% Upside May Beat CNMD?
2	BSX Looks Stronger Than TFX With 43% Return Potential
3	Why ROP With 45% Upside May Beat TFX?
4	Teleflex vs. Fortinet: Both Seem Similar Bets
5	Teleflex vs. Exelon: Both Seem Similar Bets
6	Teleflex vs. Expedia: With Return Forecast Of 12%, Teleflex Is A Better Bet
7	Teleflex vs. Domino's Pizza: Similar Market Cap, But Domino's Pizza Is A Better Bet
8	Teleflex vs. Quest Diagnostics: Similar Market Cap, Similar Bets
9	Teleflex vs. Twilio: Similar Revenue, But Twilio Is A Better Bet

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/28/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	11/6/2025	2/28/2025	2/23/2024	2/23/2023	3/1/2022	2/25/2021	2/21/2020
Key Financials
Total Revenue	3,190	3,047	2,974	2,791	2,810	2,537	2,595
EBITDA	52	434	761	731	854	651	634
Operating Income	561	546	563	514	559	462	443
Net Income	-328	70	356	363	485	335	461
EPS	-7.34	1.49	7.58	7.74	10.38	7.21	9.99
Growth Rates
Total Revenue Growth	5.4%	2.4%	6.6%	-0.7%	10.7%	-2.2%	6.0%
EBITDA Growth	-91.6%	-43.0%	4.2%	-14.4%	31.1%	2.7%	19.1%
Operating Income Growth	4.0%	-3.0%	9.6%	-8.1%	21.0%	4.1%	11.0%
Net Income Growth	-238.1%	-80.4%	-1.9%	-25.2%	44.7%	-27.3%	129.8%
Margins
EBITDA Margin	1.6%	14.2%	25.6%	26.2%	30.4%	25.7%	24.4%
Operating Income Margin	17.6%	17.9%	18.9%	18.4%	19.9%	18.2%	17.1%
Net Income Margin	-10.3%	2.3%	12.0%	13.0%	17.3%	13.2%	17.8%
Cash & Debt
Total Cash	354	290	223	292	445	376	301
Total Debt	2,769	1,755	1,926	1,832	1,966	2,564	2,010
Net Debt / (Cash)	2,415	1,465	1,704	1,540	1,521	2,189	1,709
Cash Flows
Net Cash from Operations	391	636	511	342	651	436	440
Free Cash from Operations	264	509	419	263	580	346	337
Returns to Shareholders
Dividends	61	64	64	64	64	63	63
Share Repurchases	300	200	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/28/2025	6/29/2025	3/30/2025	12/31/2024	9/29/2024	6/30/2024	3/31/2024	12/31/2023	10/1/2023	7/2/2023	4/2/2023	12/31/2022
Filing Date	11/6/2025	7/31/2025	5/1/2025	2/28/2025	10/31/2024	8/2/2024	5/3/2024	2/23/2024	11/3/2023	8/3/2023	5/4/2023	2/23/2023
Key Financials Quarterly
Total Revenue	913	781	701	795	764	750	738	774	746	743	711	758
Ebitda	-329	223	195	-36	220	187	63	150	230	205	176	188
Operating Income	113	177	130	141	144	125	136	135	166	145	117	146
Net Income	-409	123	95	-137	111	80	15	31	137	111	77	79
EPS	-9.24	2.77	2.08	-2.95	2.38	1.70	0.32	0.66	2.92	2.37	1.63	1.68
Key Financials TTM
Total Revenue TTM	3,190	3,041	3,010	3,047	3,026	3,008	3,001	2,974	2,959	2,899	2,860	2,791
Ebitda TTM	52	601	566	434	620	630	648	761	799	758	745	731
Operating Income TTM	561	593	540	546	540	561	582	563	574	535	525	514
Net Income TTM	-328	192	149	70	237	264	295	356	404	369	363	363
Growth Rates Quarterly
Total Revenue Growth	19.4%	4.2%	-5.0%	2.8%	2.4%	0.9%	3.8%	2.1%	8.7%	5.5%	10.8%	-0.5%
EBITDA Growth	-249.3%	19.2%	209.6%	-124.2%	-4.4%	-9.0%	-64.2%	-20.3%	22.0%	6.8%	8.6%	-12.1%
Operating Income Growth	-21.9%	42.3%	-4.2%	4.4%	-12.9%	-14.0%	16.1%	-7.6%	30.8%	7.4%	10.6%	-6.7%
Net Income Growth	-468.4%	53.2%	521.4%	-539.3%	-19.1%	-28.1%	-80.1%	-60.4%	34.6%	5.5%	-0.5%	-38.6%
Margins Quarterly
EBITDA Margin	-36.0%	28.5%	27.8%	-4.6%	28.8%	24.9%	8.5%	19.4%	30.9%	27.6%	24.7%	24.8%
Operating Income Margin	12.3%	22.7%	18.6%	17.7%	18.9%	16.6%	18.4%	17.4%	22.2%	19.5%	16.5%	19.3%
Net Income Margin	-44.8%	15.7%	13.6%	-17.2%	14.5%	10.7%	2.1%	4.0%	18.4%	15.0%	10.8%	10.4%
Cash & Debt
Total Cash	354	254	284	290	243	239	237	223	881	251	264	292
Total Debt	2,769	1,995	2,005	1,755	1,861	1,821	1,863	1,926	2,149	1,670	1,753	1,832
Net Debt / (Cash)	2,415	1,741	1,721	1,465	1,618	1,582	1,625	1,704	1,268	1,420	1,489	1,540
Cash Flows Quarterly
FCF from Operations	108	8	73	202	231	91	111	139	202	86	84	98
Cash Flows TTM
FCF from Operations TTM	391	514	598	636	572	543	538	511	470	411	364	342
Returns to Shareholders Quarterly
Dividends	15	15	15	16	16	16	16	16	16	16	16	16
Share Repurchases	-0	-0	300	-0	200	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	17.4%	36.9%	26.4%	38.5%	30.3%	22.5%	29.1%	14.9%	45.6%	33.7%	23.7%	26.2%
Return on Invested Capital (ROIC) TTM
ROIC TTM	23.2%	26.3%	22.3%	34.6%	30.3%	29.0%	29.6%	24.6%	36.0%	28.8%	27.0%	26.3%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Vascular access	708	684	700	658	601
Interventional	511	445	428	382	428
Surgical	427	393	378	317	370
Anesthesia	390	389	380	302	338
Original Equipment and Development Services (OEM)	326	273	246	220	221
Interventional urology	320	323	342	290	290
Other	292	285	337	367	347
Total	2,974	2,791	2,810	2,537	2,595

Price Behavior

Price Behavior

Market Price	$119.12
Market Cap ($ Bil)	5.3
First Trading Date	02/18/1988
Distance from 52W High	-36.0%
	50 Days	200 Days
DMA Price	$119.82	$125.32
DMA Trend	down	down
Distance from DMA	-0.6%	-5.0%
	3M	1YR
Volatility	41.8%	39.7%
Downside Capture	152.93	109.45
Upside Capture	85.31	51.21
Correlation (SPY)	38.5%	37.5%

TFX Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	1.46	1.30	1.29	1.21	0.76	0.81
Up Beta	0.69	0.91	1.20	1.13	0.62	0.69
Down Beta	0.05	2.11	1.88	1.98	0.93	0.87
Up Capture	116%	74%	60%	61%	33%	30%
Bmk +ve Days	13	26	39	74	142	427
Stock +ve Days	9	20	32	60	115	364
Down Capture	227%	135%	142%	122%	106%	102%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	11	22	31	66	133	382

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

1Y 5Y 10Y

Based On 1-Year Data

		Comparison of TFX With Other Asset Classes (Last 1Y)
	TFX	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-37.3%	6.9%	15.3%	58.9%	4.6%	-5.8%	-3.1%
Annualized Volatility	39.6%	17.2%	19.7%	19.4%	15.9%	17.8%	35.7%
Sharpe Ratio	-1.07	0.23	0.60	2.26	0.09	-0.48	0.04
Correlation With Other Assets		45.6%	37.7%	4.0%	3.2%	38.6%	13.0%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of TFX With Other Asset Classes (Last 5Y)
	TFX	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-20.3%	9.0%	15.0%	17.9%	11.9%	4.9%	37.1%
Annualized Volatility	32.5%	14.4%	17.1%	15.5%	18.9%	19.0%	49.1%
Sharpe Ratio	-0.63	0.44	0.71	0.93	0.52	0.17	0.64
Correlation With Other Assets		50.4%	45.3%	9.6%	6.0%	45.7%	17.8%

Based On 10-Year Data

		Comparison of TFX With Other Asset Classes (Last 10Y)
	TFX	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-0.4%	9.9%	14.5%	14.2%	5.6%	5.4%	76.3%
Annualized Volatility	31.0%	16.7%	18.0%	14.8%	17.7%	20.9%	55.9%
Sharpe Ratio	0.06	0.49	0.69	0.79	0.25	0.23	0.95
Correlation With Other Assets		56.2%	53.8%	6.1%	13.7%	49.4%	15.2%

Short Interest

Short Interest: As Of Date	11142025
Short Interest: Shares Quantity	2,351,687
Short Interest: % Change Since 10312025	27.9%
Average Daily Volume	886,354
Days-to-Cover Short Interest	2.65
Basic Shares Quantity	44,237,000
Short % of Basic Shares	5.3%

Returns Analyses

	Title
0	How Low Can Teleflex Stock Really Go?
1	Teleflex During 2008 Recession vs. 2022 Inflation Shock: TFX Stock Has 261% Upside If It Recovers To Pre-Inflation Shock Levels
2	Teleflex Stock Return Comparison
3	[10/12/2021] Teleflex (TFX) Stock Price Forecast: AI Forecasts TFX Stock Price To Be Around $368 In A Month (Up 4.8%)
4	Teleflex Total Shareholder Return (TSR): -23.6% in 2022 and -12.4% 3-yr returns (below peer average)

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11062025	10-Q 9/28/2025
6302025	7312025	10-Q 6/29/2025
3312025	5012025	10-Q 3/30/2025
12312024	2282025	10-K 12/31/2024
9302024	10312024	10-Q 9/29/2024
6302024	8022024	10-Q 6/30/2024
3312024	5032024	10-Q 3/31/2024
12312023	2232024	10-K 12/31/2023
9302023	11032023	10-Q 10/1/2023
6302023	8032023	10-Q 7/2/2023
3312023	5042023	10-Q 4/2/2023
12312022	2232023	10-K 12/31/2022
9302022	10272022	10-Q 9/25/2022
6302022	7282022	10-Q 6/26/2022
3312022	4282022	10-Q 3/27/2022
12312021	3012022	10-K 12/31/2021

Insider Activity

Expand for More

	Owner	Title	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	RANDLE STUART A		8072025	Buy	115.86	1,000	115,860	874,395	Form
1	Krakauer Andrew A		8072025	Buy	115.25	1,000	115,250	828,879	Form
2	Kelly Liam	Chairman, President & CEO	8072025	Buy	115.07	1,500	172,605	5,208,907	Form
3	Ryu Jaewon		8072025	Buy	115.00	1,500	172,500	428,605	Form
4	HAGGERTY GRETCHEN R		8072025	Buy	114.78	200	22,956	689,254	Form

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Health Care Equipment Resources

MedTech Dive

MassDevice

Fierce Medical Devices

Medical Device and Diagnostic Industry

MD+DI

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Teleflex (TFX)

Market Price (12/4/2025): $118.99 | Market Cap: $5.3 BilSector: Health Care | Industry: Health Care Equipment

Teleflex (TFX)

Market Price (12/4/2025): $118.99Market Cap: $5.3 BilSector: Health CareIndustry: Health Care Equipment

Valuation, Metrics & Events

TFX Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Teleflex (TFX)

Teleflex (TFX) - Major Customers

Capital Allocation Decisions (Last 3-5 Years)

Share Repurchases

Share Issuance

Inbound Investments

Outbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets than Teleflex (TFX)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Teleflex

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (12/4/2025): $118.99 | Market Cap: $5.3 Bil
Sector: Health Care | Industry: Health Care Equipment

Market Price (12/4/2025): $118.99
Market Cap: $5.3 Bil
Sector: Health Care
Industry: Health Care Equipment